← News
Jul 7, 2026 Psychedelics
Compass Pathways' Psilocybin Benefit Held Up at 26 Weeks — And Retreatment Helped More
Compass Pathways plc (NASDAQ: CMPS) followed its February COMP006 primary-endpoint announcement with 26-week durability data: the benefit from a single 25mg psilocybin dose largely held through six months, and patients who relapsed and got a second dose improved further — nearly 30% of early responders reached remission on retreatment. That's company-reported, ahead of peer review, about one formulation in one trial. Not a verdict on psilocybin generally.
Read at Compass Pathways